An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Trial Profile

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Bimatoprost (Primary) ; Hypromellose; Timolol; Travoprost
  • Indications Glaucoma; Ocular hypertension
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 27 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top